In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received from the European Commission a mandate to update its previous review of the existing maximum residue levels (MRLs) for thiabendazole on the basis of the new toxicological reference values as indicated in the EFSA conclusion on the peer review of thiabendazole under Regulation (EU) No 1141/2010. Based on the assessment of the available data, MRL proposals were derived and a consumer risk assessment was carried out. Some information required by the regulatory framework was missing and a possible acute risk to consumers was identified. Hence, the consumer risk assessment is considered indicative only, all MRL proposals derived by EFSA still require further consideration by risk managers and measures for reduction of the consumer exposure will also need to be considered.